The combined effect of yoga and rich in omega-3 camelina sativa powder on glycemic indices, inflammation, and oxidative stress in women with type 2 diabetes mellitus: a randomized controlled trial Authors: Haniyeh Azadi, Helda Tutunchi, Parvin Dehghan, Naimeh Mesri Alamdari, Mohammad Asghari Jafarabadi Published: 2026 ABSTRACT BackgroundThis trial evaluated the combined effect of yoga and camelina sativa powder (CSP) on glycemic indices, inflammatory and oxidative stress parameters in women with type 2 diabetes mellitus (T2DM).MethodsIn this trial, 80 patients with T2DM were randomly allocated into four groups: group 1 (placebo), group 2 (receiving CSP), group 3 (doing yoga), and group 4 (receiving CSP and doing yoga) for 8 weeks. Glycemic indices, inflammatory and oxidative stress parameters were assessed pre-and post-intervention.ResultsCSP plus yoga treatment significantly increased the McAuley-index and Quick-index compared to the placebo group (P = 0.021 and P < 0.001, respectively). A significant decrease in the glycemic exposure (GE) index (P = 0.010), fasting blood sugar (FBS) (P = 0.003), hemoglobin A1c (P = 0.013), insulin (P = 0.002), and homeostasis model assessment of insulin resistance (HOMA-IR) (P < 0.001) was found in the CSP plus yoga group compared to the placebo after adjustment for confounders. Serum superoxide dismutase level significantly increased in camelina, yoga, and both CSP plus yoga groups compared to the placebo group (P < 0.001, P = 0.019, and P = 0.005, respectively). Serum catalase levels increased significantly in CSP plus yoga group compared to the placebo following 8 weeks (P = 0.022). Malondialdehyde concentration declined significantly in yoga and CSP plus yoga groups compared to placebo (P = 0.017 and P < 0.001, respectively). Serum tumor necrosis factor-α (TNF-α) level significantly decreased in CSP, yoga, and combined CSP plus yoga groups compared with the placebo group (P < 0.001, P = 0.033, and P < 0.001, respectively).ConclusionWe found a favorable effect of co-treatment of CSP and yoga for 8 weeks in women with T2DM on some glycemic indices, oxidative stress, and inflammatory parameters. The combined effect of yoga and camelina sativa powder on glycemic indices, inflammation, and oxidative stress. PPAR-γ: peroxisome proliferator-activated receptor gamma, NF-kB: nuclear factor kappa B, GLP: glucagon-like peptide, PYY: peptide YY, SCFA: short chain fatty acids, ROS: reactive oxygen species, LPS: lipopolysaccharides, HPA: hypothalamic-pituitary-adrenal axis. Introduction Diabetes mellitus is a chronic metabolic disease characterized by unusually high blood glucose level known as hyperglycemia, that occurs as a result of decreased pancreatic insulin secretion or impaired insulin sensitivity in tissues that normally respond to insulin signaling [1]. Worldwide, diabetes affects more than 0.5 billion people [2]. The prevalence of total and diagnosed diabetes was higher in men (18% and 12.9%, respectively) than in women (13.7% and 9.7%, respectively) in U.S adults. However, the prevalence of type 2 diabetes mellitus (T2DM) in women is more than men in Iran (13.4% vs. 10.8%). Severe or poorly managed T2DM, together with associated metabolic abnormalities such as hypertension, dysregulated lipid profiles, and elevated oxidative stress, contributes to chronic low-grade inflammation and ultimately predisposes patients to progressive microvascular complications, including diabetic nephropathy, neuropathy, and retinopathy [3]. The etiology and progression of this metabolic disease is linked to oxidative stress and reactive oxygen species (ROS) generation induced by hyperglycemia [4]. Oxidative stress, which ultimately results in the development of diabetes, is caused by an imbalance between the cellular antioxidant system and ROS formation under hyperglycemic conditions [5]. ROS are produced in the phagocytic cells, peroxisomes, and endoplasmic reticulum by the mitochondrial electron transport chain (ETC) [4]. Increased ROS generation can directly lead to structural and functional alterations in proteins, lipids, and nucleic acids. Furthermore, it modifies several intracellular signaling pathways, leading to β-cell malfunction and insulin resistance [4, 6]. Beyond its metabolic burden, T2DM imposes a substantial psychological load; patients frequently experience depression, anxiety, and diabetes-related distress due to the continuous demands of self-management. These psychological challenges are clinically important because they are associated with poorer adherence, worse glycemic control, and reduced quality of life, thereby reinforcing the cycle between emotional distress and metabolic dysregulation. Given that psychological stress itself can exacerbate inflammation, oxidative stress, and insulin resistance, integrative mind–body strategies such as yoga may offer additional therapeutic value. Consequently, integrative mind–body strategies, such as yoga, may be beneficial by reducing stress, improving emotional well-being, and enhancing the psychological resilience required for long-term disease management [7, 8]. Risk factors such as genetics, nutritional factors, and lifestyle choices, such as sedentary lifestyles, are linked to T2DM [9, 10]. The American Diabetes Association recommendation has emphasized that, in addition to medication-assisted glucose control, patients and caregivers should focus on optimizing lifestyle behaviors to enhance diabetes management [11]. Generally advised lifestyle behaviors include maintaining a healthy weight, quitting smoking, drinking alcohol in moderation, eating a balanced diet, and exercising [12–14]. In persons with T2DM, nutritional strategies and physical activity have demonstrated greater advantages in preventing and managing the disease’s complications [15]. Recently, researchers have focused on improving ω-3 consumption among dietary methods because of the low ω-3 intake and low plasma levels in patients with T2DM [16]. The medicinal-oil plant belonging to the Brassicaceae family, camelina (Camelina sativa L. crantz), as a functional food, is an oilseed that is high in ω-3, phytosterols, and tocopherols. ALA Camelina seed may modulate oxidative stress, inflammation, and cardiometabolic markers, which may lead to a reduced risk of T2DM [17, 18]. The positive effectiveness of yoga has been studied in numerous studies [19]. Yoga is a mind-body exercise that combines physical postures, breathing practices, and meditation, and it has been associated with beneficial psychological effects such as reduced stress, lower anxiety, improved mood, and better emotional regulation [20]. The most common types of yoga which are done in therapeutic settings are Hatha yoga, which blends physical exercises (Asanas), meditation (Dyana), and breathing techniques (Pranayama) [21]. Hemoglobin A1c (HbA1c), homeostasis model assessment of insulin resistance (HOMA-IR), fasting blood sugar (FBS), postprandial blood glucose (PPBG), body mass index (BMI), and lipid metabolism have all been demonstrated to be markedly improved by yoga [22]. Taken together, these findings suggest that combining mind–body practices such as yoga with the consumption of functional foods rich in bioactive compounds—such as omega-3–rich Camelina sativa—may provide a complementary and potentially more effective approach for improving glycemic control, reducing inflammation and oxidative stress, and supporting the overall management of T2DM. According to our knowledge, the synergistic effect of yoga training and camelina sativa powder (CSP) as a source of ω-3, antioxidants, fiber, and other components has not been assessed in patients with T2DM. Therefore, this randomized controlled trial aimed to investigate the effect of camellia powder with and without yoga training on glycemic indices, inflammation, and oxidative stress in women with T2DM. Materials and methods Study design and patients This single-center, randomized, controlled parallel trial was conducted between 2024 July and 2025 May 2025. About 80 women with T2DM aged 30–55 years old were engaged from the clinics of Tabriz University of Medical Sciences (Tabriz, Iran), through a referral letter from a physician according to the inclusion and exclusion criteria. The inclusion criteria were: Women willing and able to give informed consent for participation in the trial diagnosed with T2DM for at least 6 months; 25 ≤ BMI < 35 kg/m2; no weight changes during the last 3 months; no insulin injection and stable dose of regular diabetes medication for at least 4 weeks prior to trial entry and during of trial; had no course of any dietary supplement intake especially omega-3 fatty acids in the three months before the study initiation; haven’t practiced yoga in the last 3 months; not engaging in other physical activities during the study. The exclusion criteria were: females who were pregnant; lactating; menopausal sate; any significant diseases such as thyroid; kidney; liver disorders and pulmonary disorders; anemia (Hb < 12 g/dl); cardiovascular diseases; infectious diseases; malignancies and cognitive disorders which may influence the result of the trial; taking insulin; glucocorticoids; laxatives; anti-obesity drugs; nonsteroidal anti-inflammatory drugs (NSAIDs); antidepressants; antibiotics; hormone therapy; and food supplements within 3 months prior to enrollment; musculoskeletal injuries; smoking and alcohol consumption; a history of a weight loss or a special diet in the last 6 months. The study protocol was approved by the ethics committee of the Tabriz University of Medical Sciences (TBZMED) and has been registered in the “Iranian Registry of Clinical Trials” website with the number of IRCT20150205020965N12. An informed consent form was signed by the participants at the beginning of the trial. Sample size Sample size calculation was based on the mean changes of hs-CRP levels reported by Jacobo-Cejudo et al.'s study, using power analysis and sample size software (PASS; NCSS, LLC, US) was estimated about 17 in each study arm considering the 80% power and a 95% confidence interval. Assuming a dropout rate of approximately 15%, the number of patients in each group was expanded to 20 [23]. Randomization, allocation concealment, blinding, interventions, and monitoring This randomized, controlled, four-arm parallel trial was conducted on 80 patients with T2DM. Eligible participants were stratified according to BMI and subsequently randomized into four groups: Placebo, CSP, yoga training, and CSP plus yoga training, for 8-week intervention period. Randomization was performed using a permuted block randomization method with blocks of four. An independent statistician, who was not involved in any part of the intervention, generated the allocation sequence using Random Assignment Software (RAS). The randomization list was provided to the investigators in sealed order, and participants were assigned equally to the four study groups based on the obtained sequences. Allocation concealment was fully ensured. CSP and placebo sachets were packaged by the manufacturing factory in identical containers and labeled only with anonymous numerical codes (“1” and “2”). The true content of each code was not revealed to the investigators, research assistants, yoga instructor, data collectors, or the statistical consultant until completion of the final statistical analysis. Due to the nature of the exercise intervention, blinding was only feasible for the supplement component. Participants were blinded to whether they received CSP or placebo; however, blinding to the yoga intervention was not possible. To maintain participant blinding for the supplement, a colored placebo containing a food-grade flavoring agent was used to match the distinct natural color and flavor of CSP. All sachets were indistinguishable in color, odor, and taste. Investigators, research assistants, yoga instructors, data collectors, and the statistical consultant remained blinded to all group allocations throughout the study. Participants in the CSP groups and placebo groups consumed one sachet containing 30 g of CSP (Bistun Shafa Co., Kermanshah, Iran) or placebo (Jiujiang Hurirong Trade Co., China). twice daily, at lunch and dinner mixed with food (e.g., soup, salad, or other meals). The chemical composition of CSP is presented in Table 1.Table 1Compositions of camelina seeds.% 28–40ω-3Fat (% 33–40)% 29.96–32.73Linolenic acid% 18.18–18.52Linoleic acid% 19.77–20.47Oleic acid% 11.51–13.06Eicosenoic acids--MonosaccharidesCarbohydrate% 5.5SucroseDisaccharides<% 1Raffinose, stachyoseOligosaccharides<% 1Starchpolysaccharides<% 1Pectin% 6.7Mucilage-CelluloseFiber-Hemicellulose% 7.4Lignan% 24–31Protein990.42–1081.75 mg/kgTocopherolVitamins18 μg/gB1194 μg/gB311 μg/gB5% 1–1.6CaMinerals329 μg/gFe40 μg/gMn69 μg/gZn-K, P Table 1Compositions of camelina seeds.% 28–40ω-3Fat (% 33–40)% 29.96–32.73Linolenic acid% 18.18–18.52Linoleic acid% 19.77–20.47Oleic acid% 11.51–13.06Eicosenoic acids--MonosaccharidesCarbohydrate% 5.5SucroseDisaccharides<% 1Raffinose, stachyoseOligosaccharides<% 1Starchpolysaccharides<% 1Pectin% 6.7Mucilage-CelluloseFiber-Hemicellulose% 7.4Lignan% 24–31Protein990.42–1081.75 mg/kgTocopherolVitamins18 μg/gB1194 μg/gB311 μg/gB5% 1–1.6CaMinerals329 μg/gFe40 μg/gMn69 μg/gZn-K, P Compositions of camelina seeds. The yoga intervention was conducted for 8 weeks, consisting of 24 sessions based on a modified protocol described in Table 2 [24]. All sessions were supervised by a certified yoga instructor, held indoors at a sports club, and scheduled at predetermined times for each group to prevent contact between participants in different treatment arms.Table 2Yoga training sessions protocol [24].Time (min)Curriculum elements2Beginning prayer: Lord, don’t keep me in an unreal world; But lead me to reality - don’t keep me in the dark; Rather, make me go to the light16Joint relaxing (strengthening) exercises, safe, rhythmic, and repetitive stretching movements- Upward Dog (3 rounds)- Hands behind the waist—bend back and bend forward with inhalation and exhalation3 turns clockwise3 anti-clockwise turns29Legs wider than shoulder width apart—hands above head, upper body stretch lock on legs on both sides—sun salutation chaina - 10 quick steps (6 rounds)b - 12 slow steps, 1 round315Asanas (movements), poses, and physical positions (each asana 1 min)1-StandingSimple triangle movement - inverted triangle—legs wider than shoulder width apart —bend down and hands on the floor, exhale and exhale, bend and open the hands and the upper body goes up and down a little2- lying on the backAbdominal rotation or spinal twist in a lying position—on the back of the lying position, bend the legs from the knees and hold them inside the abdomen with the hands—we take the upper pair of legs with the hands from the waist, only the shoulders are on the floor (similar to the movement of the candle in gymnastics)3- CobraThe bow position or similar to the basket movement (lying on the stomach with the hands pulls the legs from the back)4- SeatsFrog movement—seated spinal twist—legs straight, upper body stretched forward on legs—more movement— relaxing with seated abdominal breathing (10–15 rounds of 2 min)43a-sits in a sitting position, inhales from one nostril and exhales through the next and vice versa (blocks one of the nostrils with his hand)b- In a comfortable sitting position, he covers the eyes, mouth and ears with the help of his fingers and only the nose is open, then he takes a deep breath.59Pranayama (controlled breathing)615Meditation (for stress management and deep and quiet relaxation), cyclical meditation71Solution (I am completely healthy)81Final prayer960Total Table 2Yoga training sessions protocol [24].Time (min)Curriculum elements2Beginning prayer: Lord, don’t keep me in an unreal world; But lead me to reality - don’t keep me in the dark; Rather, make me go to the light16Joint relaxing (strengthening) exercises, safe, rhythmic, and repetitive stretching movements- Upward Dog (3 rounds)- Hands behind the waist—bend back and bend forward with inhalation and exhalation3 turns clockwise3 anti-clockwise turns29Legs wider than shoulder width apart—hands above head, upper body stretch lock on legs on both sides—sun salutation chaina - 10 quick steps (6 rounds)b - 12 slow steps, 1 round315Asanas (movements), poses, and physical positions (each asana 1 min)1-StandingSimple triangle movement - inverted triangle—legs wider than shoulder width apart —bend down and hands on the floor, exhale and exhale, bend and open the hands and the upper body goes up and down a little2- lying on the backAbdominal rotation or spinal twist in a lying position—on the back of the lying position, bend the legs from the knees and hold them inside the abdomen with the hands—we take the upper pair of legs with the hands from the waist, only the shoulders are on the floor (similar to the movement of the candle in gymnastics)3- CobraThe bow position or similar to the basket movement (lying on the stomach with the hands pulls the legs from the back)4- SeatsFrog movement—seated spinal twist—legs straight, upper body stretched forward on legs—more movement— relaxing with seated abdominal breathing (10–15 rounds of 2 min)43a-sits in a sitting position, inhales from one nostril and exhales through the next and vice versa (blocks one of the nostrils with his hand)b- In a comfortable sitting position, he covers the eyes, mouth and ears with the help of his fingers and only the nose is open, then he takes a deep breath.59Pranayama (controlled breathing)615Meditation (for stress management and deep and quiet relaxation), cyclical meditation71Solution (I am completely healthy)81Final prayer960Total Yoga training sessions protocol [24]. Joint relaxing (strengthening) exercises, safe, rhythmic, and repetitive stretching movements - Upward Dog (3 rounds) - Hands behind the waist—bend back and bend forward with inhalation and exhalation 3 turns clockwise 3 anti-clockwise turns Legs wider than shoulder width apart—hands above head, upper body stretch lock on legs on both sides—sun salutation chain a - 10 quick steps (6 rounds) b - 12 slow steps, 1 round Asanas (movements), poses, and physical positions (each asana 1 min) 1-Standing Simple triangle movement - inverted triangle—legs wider than shoulder width apart —bend down and hands on the floor, exhale and exhale, bend and open the hands and the upper body goes up and down a little 2- lying on the back Abdominal rotation or spinal twist in a lying position—on the back of the lying position, bend the legs from the knees and hold them inside the abdomen with the hands—we take the upper pair of legs with the hands from the waist, only the shoulders are on the floor (similar to the movement of the candle in gymnastics) 3- Cobra The bow position or similar to the basket movement (lying on the stomach with the hands pulls the legs from the back) 4- Seats Frog movement—seated spinal twist—legs straight, upper body stretched forward on legs—more movement— relaxing with seated abdominal breathing (10–15 rounds of 2 min) a-sits in a sitting position, inhales from one nostril and exhales through the next and vice versa (blocks one of the nostrils with his hand) b- In a comfortable sitting position, he covers the eyes, mouth and ears with the help of his fingers and only the nose is open, then he takes a deep breath. Adherence to supplement intake was assessed by counting returned unused sachets. Participants with a consumption rate of ≥90% were considered adherent. Additionally, participants were provided with a daily checklist to record each occasion of powder consumption. Monthly sachet packages were distributed, and unused sachets were collected at monthly visits. Adherence to the yoga intervention was evaluated based on the number of attended sessions. Participants who missed more than two yoga sessions or consumed less than 90% of the prescribed sachets were excluded from the study. Participants were instructed to report any changes in diet, physical activity, lifestyle habits, or modifications in the dosage or class of their hypoglycemic medications during the intervention period. Measurments The individuals’ height (Siber-Hegner, Switzerland, 1 cm accuracy) and weight (Seca, Hamburg, Germany, to the nearest 0.5 kg) were measured while the patients wore no shoes and had light clothes on. BMI was computed as the body weight (kg) divided by the square of the height (m) [25]. The dietary intake was assessed using a 3-day food diary (2 weekdays and 1 weekend) before starting the trial and also at the end of the study during last week. “Nutritionist 4” (First Databank Inc., Hearst Corp., and San Bruno, CA, USA) was used to assess dietary intake composition data. The physical activity level (PAL) of the participants was evaluated using the International Physical Activity Questionnaire [26] before and after intervention. Biochemical measurements A venous blood sample (5 ml) was collected from every patient at baseline and end of the study after overnight fasting. FBS and uric acid were measured via the enzymatic method by an autoanalyzer using kits (Pars-Azmoon Co., Tehran, Iran). Insulin concentration was determined using a chemiluminescent immunoassay method. The level of HbA1c was measured by chromatography. The activity levels of total antioxidant capacity (TAC), glutathione peroxidase (GPX), superoxide dismutase (SOD) and total oxidant status (TOS) were measured through a colorimetric method (TAC: RANDOX kits, GSH-Px: RANSEL kits and SOD: RANSOD kits; RANDOX Laboratory, UK, TOS: ZellBio GmbH, Ulm, Germany) by an automatic analyzer. Malondialdehyde (MDA) levels were determined by spectrofluorometer (Kontron, model SFM 25 A, Italy) [27]. C-peptide, and tumor necrosis factor alpha TNF-α (concentrations were estimated using an enzyme linked immunosorbent assay (ELISA) kits (C-peptide: EIA1293, DRG International, Inc., USA, TNF-α: AviBion Kit, Orgenium Inc., Finland). The level of high-sensitivity C-reactive protein (hs-CRP) in serum was measured using an immunoturbidimetric technique (Pars Azmoon, Tehran, Iran). The method of Aebi was applied to determine catalase activity [28]. The formula used to calculate the oxidative stress index (OSI) was as follows: [(TOS, μmol/l)/ (TAC, μmol/l) × 100] [29]. Glucose homeostasis The glycemic exposure (GE) index was calculated using the following equation: GE index = (HbA1c)1/2 × (duration of DM in years)1/8 [30]. The subsequent formulas were used to calculate the homeostasis model assessment of insulin resistance (HOMA-IR) [31], the quantitative insulin sensitivity check index (QUICKI) [32], homeostasis model assessment of β-cell function (HOMA-B) [33] and McAuley’s index [34]: HOMA-IR = [fasting insulin (µU/mL) × FBS (mM/L)]/22.5 QUICKI = 1/(log (fasting insulin, µU/ml) + log (FBS, mg/dl)) McAuley Index = Exp [2.63 − 0.28 × Ln (fasting insulin (IU/mL)) − 0.31 × Ln (Triglycerides (mmol/L)] HOMA-B = [20 fasting insulin {µIU/ml}/FG {mmol/l} _ 3.5]) Outcomes The primary outcome of the study was hs-CRP, oxidative stress, and antioxidant biomarkers, including TAC, MDA, GPX, SOD, catalase, uric acid, OSI, FBS, insulin, HbA1c, HOMA-IR, McAuley’s index, GE index, HOMA-B, QUICKI, and TNF-α. The secondary outcomes were anthropometric measurements, including weight and BMI. All variables were measured at baseline at the end of the study. Statistical analyses Statistical analysis was conducted using Statistical Package for the Social Sciences (SPSS, version 24, Chicago, IL, USA). Analyses were conducted on pre-protocol approach. The normal distribution of the data was evaluated using the Kolmogorov-Smirnov test. Log transformation was done when the data was not normally distributed. Data were presented as mean (SD) for numerical data, frequency (percentage) for categorical variables, and median (25th, 75th) for values with skewed distribution. For comparison of before and after values, a paired sample t-test was used. An ANOVA test was done for Pre-intervention comparisons. An analysis of covariance test (ANCOVA) was used to adjust the effects of pre-intervention values, changes in the values of the considered variables, and confounding factors. The significance level was defined at P-value < 0.05. Results Out of the 80 patients who enrolled in the study, 78 completed the trial, one patient in the placebo and yoga arms stopped the study because of travel-related and personal reasons. Patients did not report any undesirable effects related to any applied interventions. The flowchart of the study is shown in Fig. 1. There were no significant differences in the baseline characteristics, including age, BMI, diabetes duration, education level, and PAL levels among the four groups (Table 3).Fig. 1Flowchart of the study.Table 3Baseline characteristics of study population.The study groupVariables bPlacebo n = 19CSP n = 20Yoga n = 19CSP+ yoga n = 20P-valueaAge (year)49 (45.0)48 (44.0)45 (40.0)45 (42.0)0.505BMI (kg/m2)33.34 (2.73)34.83 (3.31)31.79 (3.15)32.26 (4.48)0.106Diabetes duration, n(%) (year)4 (2.0)5 (3.0)6 (3.5)7 (5.0)0.689Education level, n (%)0.305Elementary7 (50.0)5 (33.3)1 (7.7)7 (46.7)High-school2 (14.3)2 (13.3)4 (30.8)2 (13.3)University degree5 (35.7)8 (53.3)8 (61.5)6 (40.0)PAL, n (%)0.217Light5 (26.32)5 (25)7(36.84)6(30)Moderate13 (68.42)14 (70)10(52.63)11(55)Vigorous1 (5.26)1 (5)2(10.52)3(15)MedicationsMetformin 500 mg, (tablets/day) n (%)0.1060/15 (35.7)0 (0.0)3 (23.1)4 (26.7)2+9 (64.3)15(100.0)10(76.9)11(73.3)Glibenclamide, 5 mg (tablets/day) n (%)0.2010/111 (78.6)9 (60.0)5 (38.5)8 (53.3)2 + 3 (21.4)6 (40.0)8 (61.5)7 (46.7)CSP Camelina seed powder, PAL physical activity level.aP-value based on Fisher’s exact test and ANOVA test.bcontinuous variables are presented as mean(SD) for normally distributed data. Categorical variables are presented as numbers (percentage). Flowchart of the study. Table 3Baseline characteristics of study population.The study groupVariables bPlacebo n = 19CSP n = 20Yoga n = 19CSP+ yoga n = 20P-valueaAge (year)49 (45.0)48 (44.0)45 (40.0)45 (42.0)0.505BMI (kg/m2)33.34 (2.73)34.83 (3.31)31.79 (3.15)32.26 (4.48)0.106Diabetes duration, n(%) (year)4 (2.0)5 (3.0)6 (3.5)7 (5.0)0.689Education level, n (%)0.305Elementary7 (50.0)5 (33.3)1 (7.7)7 (46.7)High-school2 (14.3)2 (13.3)4 (30.8)2 (13.3)University degree5 (35.7)8 (53.3)8 (61.5)6 (40.0)PAL, n (%)0.217Light5 (26.32)5 (25)7(36.84)6(30)Moderate13 (68.42)14 (70)10(52.63)11(55)Vigorous1 (5.26)1 (5)2(10.52)3(15)MedicationsMetformin 500 mg, (tablets/day) n (%)0.1060/15 (35.7)0 (0.0)3 (23.1)4 (26.7)2+9 (64.3)15(100.0)10(76.9)11(73.3)Glibenclamide, 5 mg (tablets/day) n (%)0.2010/111 (78.6)9 (60.0)5 (38.5)8 (53.3)2 + 3 (21.4)6 (40.0)8 (61.5)7 (46.7)CSP Camelina seed powder, PAL physical activity level.aP-value based on Fisher’s exact test and ANOVA test.bcontinuous variables are presented as mean(SD) for normally distributed data. Categorical variables are presented as numbers (percentage). Baseline characteristics of study population. CSP Camelina seed powder, PAL physical activity level. aP-value based on Fisher’s exact test and ANOVA test. bcontinuous variables are presented as mean(SD) for normally distributed data. Categorical variables are presented as numbers (percentage). According to the results of study, BMI decreased significantly about −9.75% (P < 0.001) in CSP group, −5.25% (P = 0.093) in yoga group and about –5.87% (P = 0.006) in CSP plus yoga group compared with the placebo group. Antioxidant related dietary intake The effects of CSP, yoga and combined CSP plus yoga on antioxidant related dietary intake of patients are presented in Table 4. There were no significant changes in vitamin A, vitamin C, and vitamin E intakes in any groups compared with baseline. The differences between groups were not significant in terms of vitamin A, vitamin C, and vitamin E after adjusting for baseline values and confounding variables (P = 0.380, P = 0.484, and P = 0.063, respectively, Table 4).Table 4Antioxidant related dietary intake of study groups before and after intervention.The study groupVariablesPlacebo n = 19CSP n = 20Yoga n = 19 CSP+ yoga n = 20P-value***Vitamin A (RAE)Before955.97 (534.42)792.29 (929.27)917.14 (712.75)1148.92 (603.66)0.592**After1261.10 (611.99)562.55 (285.78)1086.00 (566.52)1116.97 (795.54)0.380MD, 95% CI305.13 (−181.50– 791.76)−229.74 (−739.54– 280.06)168.86 (−371.43– 709.16)−31.95 (−527.41– 463.51)P-value*0.1990.3500.5090.892Vitamin C (mg/d)Before92.94 (64.71)89.54 (29.70)98.80 (27.77)100.78 (32.78)0.875**After114.10 (38.83)92.78 (34.35)88.80 (31.74)96.22 (32.93)0.484MD, 95%CI21.16 (−19.85– 62.16)3.24 (−20.61 –27.09)−9.99 (−33.61– 13.63)−4.56 (−31.44– 22.32)P-value*0.2850.7750.3750.721Vitamin E (mg/d)Before2.78 (1.82)4.60 (3.29)1.78 (1.88)2.89 (1.45)0.200**After3.02 (1.68)4.44 (2.78)3.61 (1.67)2.91 (1.86)0.063MD, 95% CI0.24 (−0.10–0.59)−0.16 (−0.63 –0.32)1.83 (1.34– 2.31)0.01 (−0.31–0.33)P-value*0.6080.8790.0800.980Means ± SD are presented for normally distributed data.P-value * was reported based on paired sample t test.P-value ** was reported based on ANOVA for Pre-intervention.P-value *** was reported based on analysis of covariance (ANCOVA) after adjustment of Pre-intervention and potential confounder as education, drugs, age, duration, energy and BMI changes.CSP Camelina seed powder, MD mean difference (mean after − mean before). Table 4Antioxidant related dietary intake of study groups before and after intervention.The study groupVariablesPlacebo n = 19CSP n = 20Yoga n = 19 CSP+ yoga n = 20P-value***Vitamin A (RAE)Before955.97 (534.42)792.29 (929.27)917.14 (712.75)1148.92 (603.66)0.592**After1261.10 (611.99)562.55 (285.78)1086.00 (566.52)1116.97 (795.54)0.380MD, 95% CI305.13 (−181.50– 791.76)−229.74 (−739.54– 280.06)168.86 (−371.43– 709.16)−31.95 (−527.41– 463.51)P-value*0.1990.3500.5090.892Vitamin C (mg/d)Before92.94 (64.71)89.54 (29.70)98.80 (27.77)100.78 (32.78)0.875**After114.10 (38.83)92.78 (34.35)88.80 (31.74)96.22 (32.93)0.484MD, 95%CI21.16 (−19.85– 62.16)3.24 (−20.61 –27.09)−9.99 (−33.61– 13.63)−4.56 (−31.44– 22.32)P-value*0.2850.7750.3750.721Vitamin E (mg/d)Before2.78 (1.82)4.60 (3.29)1.78 (1.88)2.89 (1.45)0.200**After3.02 (1.68)4.44 (2.78)3.61 (1.67)2.91 (1.86)0.063MD, 95% CI0.24 (−0.10–0.59)−0.16 (−0.63 –0.32)1.83 (1.34– 2.31)0.01 (−0.31–0.33)P-value*0.6080.8790.0800.980Means ± SD are presented for normally distributed data.P-value * was reported based on paired sample t test.P-value ** was reported based on ANOVA for Pre-intervention.P-value *** was reported based on analysis of covariance (ANCOVA) after adjustment of Pre-intervention and potential confounder as education, drugs, age, duration, energy and BMI changes.CSP Camelina seed powder, MD mean difference (mean after − mean before). Antioxidant related dietary intake of study groups before and after intervention. Means ± SD are presented for normally distributed data. P-value * was reported based on paired sample t test. P-value ** was reported based on ANOVA for Pre-intervention. P-value *** was reported based on analysis of covariance (ANCOVA) after adjustment of Pre-intervention and potential confounder as education, drugs, age, duration, energy and BMI changes. CSP Camelina seed powder, MD mean difference (mean after − mean before). Glycemic indices The effects of CSP, yoga, and combined CSP plus yoga on the glycemic indices are presented in Table 5. Within group comparisons showed that, supplementation with CSP, yoga performance, alone or their combinations significantly promoted glucose homeostasis parameters including McAuley-index and Quick-index compared with baseline. Moreover, ANCOVA test represented a significant difference between groups after intervention. Two-by-two comparisons showed significant increment of McAuley-index in CSP plus yoga group relative to placebo group (P = 0.021). A significant increase was observed in CSP plus yoga group about Quick-index compared to placebo and yoga groups (P < 0.001 and P = 0.033, respectively). Paired t-test analysis indicated a significant reduction in GE index, FBS, HbA1c, insulin, and HOMA-IR in CSP, yoga, and combined CSP plus yoga groups. Furthermore, significant differences between the four study groups in mean GE index, FBS, HbA1c, insulin, and HOMA-IR were noticed (P = 0.006, P = 0.003, P = 0.010, P = 0.003, and P=0.006 , respectively). Pairwise comparisons of the groups showed a significant decrement in GE index in CSP plus yoga and yoga groups relative to placebo groups (P = 0.010 and P = 0.023, respectively). Additionally, two-by-two comparisons showed a significant decline of FBS levels in CSP plus yoga group relative to placebo and yoga groups (P = 0.003 and P = 0.038, respectively). Two-by-two comparisons across groups revealed that HbA1c reduced significantly in CSP plus yoga group and yoga group relative to placebo group (P = 0.013 and P = 0.026, respectively). Insulin levels decreased significantly in CSP plus yoga group compared with placebo (P = 0.002). HOMA-IR levels declined in camelia plus yoga group compared to placebo, camelina, and yoga groups (P < 0.001, P = 0.017, and P = 0.033, respectively). In terms of c-peptide and HOMA-B, although interventions (CSP and combinations of CSP plus yoga) administration for eight weeks decreased mentioned parameters relative to baseline values, between group comparisons showed no significant change following baseline values and confounding factors adjustments.Table 5Comparing the glycemic indices in study groups before and after intervention.The study groupVariablesPlacebo n = 19CSP n = 20Yoga n = 19CSP + yoga n = 20P-value ***McAuley_ indexBefore2.85 (0.20)2.77 (0.26)2.74 (0.22)2.70 (0.29)0.419**After2.83 (0.18)3.08 (0.34)3.08 (0.31)3.07 (0.48) a0.020MD, 95% CI−0.02 (−0.09 –0.05)0.31 (0.18–0.44)0.33 (0.24–0.42)0.37 (0.17–0.57)P-value*0.487<0.001<0.0010.001GE_indexBefore3.36 (0.47)3.36 (0.36)3.49 (0.39)3.54 (0.28)0.475**After3.35 (0.44)3.31 (0.37)3.33 (0.42) a3.39 (0.26) a0.006MD, 95% CI−0.01 (−0.05 –0.04)−0.06 (−0.10 to −0.01)−0.17 (−0.25 to −0.09)−0.15 (−0.18 to −0.12)P-value*0.6660.014<0.001<0.001FBS (mg/dl) Before162.36 (19.17)160.80 (12.88)167.46 (16.32)171.93 (13.60)0.209** After163.79 (17.65)157.33 (12.90)156.54 (24.27)151.20 (15.67)a,b0.003MD, 95% CI1.43 (−5.98–8.84)−3.47 (−8.86–1.93)−10.92 (−19.50 to −2.35)−20.73 (−28.15 to −13.32) P-value*0.6840.01900.017<0.001HbA1c (%) Before7.73 (0.75)7.57 (0.36)7.96 (0.58)7.90 (0.31)0.198** After7.72 (0.75)7.30 (0.25)7.19 (0.68)a7.25 (0.30)a0.010MD, 95% CI−0.01 (−0.20– 0.18)−0.27 (−0.47 to −0.07)−0.77 (−1.10 to −0.44)−0.65 (−0.78 to −0.53)P-value*0.9240.011<0.001<0.001Insulin (μU ml−1) Before11.59 (1.86)12.26 (3.05)11.93 (1.70)13.66 (3.62)0.195** After11.49 (1.51)9.87 (2.98)9.96 (2.13)9.31 (3.03) a0.003MD, 95% CI−0.11 (−0.68– 0.47)−2.39 (−3.49 to −1.29)−1.97 (−2.93 to −1.00)−4.35 (−5.59 to −3.11)P-value*0.695<0.001<0.001<0.001C-peptide (ng/ml) Before5.31 (1.07)5.11 (0.87)4.88 (0.60)5.70 (1.13)0.135 After5.44 (1.13)4.37 (0.98)4.57 (1.02)4.58 (1.09)0. 460MD, 95% CI0.13 (−0.29 –0.55)−0.74 (−1.45 to −0.03)−0.31 (−0.97 –0.36)−1.12 (−1.86 to −0.38)P-value*0.5240.0420.3320.006HOMA-IR Before4.66 (1.02)4.86 (1.21)4.93 (0.86)5.79 (1.56)<0.001 After4.64 (0.74)3.87 (1.29)3.88 (1.21)3.48 (1.17)a,b,c0.006MD, 95% CI−0.03 (−0.36– 0.31)−0.99 (−1.38 to −0.60)−1.05 (−1.52 to −0.59)−2.32 (−2.83 to −1.80)P-value*0.867<0.001<0.001<0.001Quick-index Before0.31 (0.01)0.31 (0.01)0.30 (0.01)0.30 (0.01)0.188 After0.31 (0.01)0.32 (0.02)0.32 (0.01)0.32 (0.02)a,b<0.001MD, 95% CI0.00 (0.00–0.00)0.01 (0.01–0.02)0.01 (0.01– 0.02)0.02 (0.02–0.03)P-value*0.8030.001<0.001<0.001HOMA-B Before43.30 (10.26)45.94 (13.65)42.31 (10.56)45.88 (13.88)0.815 After42.26 (9.35)37.76 (11.71)40.75 (13.75)39.23 (16.10)0.551MD,95% CI−1.04 (−5.08– 2.99)−8.18 (−13.77 to −2.59)−1.56 (−6.10–2.99)−6.64 (−13.43–0.14) P-value*0.5860.0070.4700.054Means ± SD are presented for normally distributed data.P-value* was reported based on paired sample t test.P-value** was reported based on ANOVA for Pre-intervention.P-value*** was reported based on analysis of covariance (ANCOVA) after adjustment of Pre-intervention and potential confounder as education, drugs, age, duration, energy and BMI.CSP Camelina seed powder, MD mean difference (mean after – mean before), FBS fasting blood sugar, GE_ index glycemic exposure index, HbA1c hemoglobin A1c, Homa-IR homeostasis model assessment of insulin resistance, Quick-index quantitative insulin sensitivity checks, Homa-B homeostasis model assessment of β-cell function.aP-value less than 0.05 vs. placebo group.bP-value less than 0.05 vs. camelina group.cP-value less than 0.05 vs. yoga group.dP-value less than 0.05 vs. camelina plus yoga group. Table 5Comparing the glycemic indices in study groups before and after intervention.The study groupVariablesPlacebo n = 19CSP n = 20Yoga n = 19CSP + yoga n = 20P-value ***McAuley_ indexBefore2.85 (0.20)2.77 (0.26)2.74 (0.22)2.70 (0.29)0.419**After2.83 (0.18)3.08 (0.34)3.08 (0.31)3.07 (0.48) a0.020MD, 95% CI−0.02 (−0.09 –0.05)0.31 (0.18–0.44)0.33 (0.24–0.42)0.37 (0.17–0.57)P-value*0.487<0.001<0.0010.001GE_indexBefore3.36 (0.47)3.36 (0.36)3.49 (0.39)3.54 (0.28)0.475**After3.35 (0.44)3.31 (0.37)3.33 (0.42) a3.39 (0.26) a0.006MD, 95% CI−0.01 (−0.05 –0.04)−0.06 (−0.10 to −0.01)−0.17 (−0.25 to −0.09)−0.15 (−0.18 to −0.12)P-value*0.6660.014<0.001<0.001FBS (mg/dl) Before162.36 (19.17)160.80 (12.88)167.46 (16.32)171.93 (13.60)0.209** After163.79 (17.65)157.33 (12.90)156.54 (24.27)151.20 (15.67)a,b0.003MD, 95% CI1.43 (−5.98–8.84)−3.47 (−8.86–1.93)−10.92 (−19.50 to −2.35)−20.73 (−28.15 to −13.32) P-value*0.6840.01900.017<0.001HbA1c (%) Before7.73 (0.75)7.57 (0.36)7.96 (0.58)7.90 (0.31)0.198** After7.72 (0.75)7.30 (0.25)7.19 (0.68)a7.25 (0.30)a0.010MD, 95% CI−0.01 (−0.20– 0.18)−0.27 (−0.47 to −0.07)−0.77 (−1.10 to −0.44)−0.65 (−0.78 to −0.53)P-value*0.9240.011<0.001<0.001Insulin (μU ml−1) Before11.59 (1.86)12.26 (3.05)11.93 (1.70)13.66 (3.62)0.195** After11.49 (1.51)9.87 (2.98)9.96 (2.13)9.31 (3.03) a0.003MD, 95% CI−0.11 (−0.68– 0.47)−2.39 (−3.49 to −1.29)−1.97 (−2.93 to −1.00)−4.35 (−5.59 to −3.11)P-value*0.695<0.001<0.001<0.001C-peptide (ng/ml) Before5.31 (1.07)5.11 (0.87)4.88 (0.60)5.70 (1.13)0.135 After5.44 (1.13)4.37 (0.98)4.57 (1.02)4.58 (1.09)0. 460MD, 95% CI0.13 (−0.29 –0.55)−0.74 (−1.45 to −0.03)−0.31 (−0.97 –0.36)−1.12 (−1.86 to −0.38)P-value*0.5240.0420.3320.006HOMA-IR Before4.66 (1.02)4.86 (1.21)4.93 (0.86)5.79 (1.56)<0.001 After4.64 (0.74)3.87 (1.29)3.88 (1.21)3.48 (1.17)a,b,c0.006MD, 95% CI−0.03 (−0.36– 0.31)−0.99 (−1.38 to −0.60)−1.05 (−1.52 to −0.59)−2.32 (−2.83 to −1.80)P-value*0.867<0.001<0.001<0.001Quick-index Before0.31 (0.01)0.31 (0.01)0.30 (0.01)0.30 (0.01)0.188 After0.31 (0.01)0.32 (0.02)0.32 (0.01)0.32 (0.02)a,b<0.001MD, 95% CI0.00 (0.00–0.00)0.01 (0.01–0.02)0.01 (0.01– 0.02)0.02 (0.02–0.03)P-value*0.8030.001<0.001<0.001HOMA-B Before43.30 (10.26)45.94 (13.65)42.31 (10.56)45.88 (13.88)0.815 After42.26 (9.35)37.76 (11.71)40.75 (13.75)39.23 (16.10)0.551MD,95% CI−1.04 (−5.08– 2.99)−8.18 (−13.77 to −2.59)−1.56 (−6.10–2.99)−6.64 (−13.43–0.14) P-value*0.5860.0070.4700.054Means ± SD are presented for normally distributed data.P-value* was reported based on paired sample t test.P-value** was reported based on ANOVA for Pre-intervention.P-value*** was reported based on analysis of covariance (ANCOVA) after adjustment of Pre-intervention and potential confounder as education, drugs, age, duration, energy and BMI.CSP Camelina seed powder, MD mean difference (mean after – mean before), FBS fasting blood sugar, GE_ index glycemic exposure index, HbA1c hemoglobin A1c, Homa-IR homeostasis model assessment of insulin resistance, Quick-index quantitative insulin sensitivity checks, Homa-B homeostasis model assessment of β-cell function.aP-value less than 0.05 vs. placebo group.bP-value less than 0.05 vs. camelina group.cP-value less than 0.05 vs. yoga group.dP-value less than 0.05 vs. camelina plus yoga group. Comparing the glycemic indices in study groups before and after intervention. Means ± SD are presented for normally distributed data. P-value* was reported based on paired sample t test. P-value** was reported based on ANOVA for Pre-intervention. P-value*** was reported based on analysis of covariance (ANCOVA) after adjustment of Pre-intervention and potential confounder as education, drugs, age, duration, energy and BMI. CSP Camelina seed powder, MD mean difference (mean after – mean before), FBS fasting blood sugar, GE_ index glycemic exposure index, HbA1c hemoglobin A1c, Homa-IR homeostasis model assessment of insulin resistance, Quick-index quantitative insulin sensitivity checks, Homa-B homeostasis model assessment of β-cell function. aP-value less than 0.05 vs. placebo group. bP-value less than 0.05 vs. camelina group. cP-value less than 0.05 vs. yoga group. dP-value less than 0.05 vs. camelina plus yoga group. Oxidative stress status and inflammatory indices Changes in the oxidative stress status, antioxidant and inflammatory biomarkers are shown in Table 6. Regarding antioxidant capacity, after two months of interventions, the mean TAC and SOD increased significantly in CSP, yoga, and combined CSP plus yoga groups relative to baseline. However, between group comparisons revealed no significant change in TAC levels (P = 0.182). About SOD, between group comparisons showed a significant increment in CSP, yoga, and both CSP plus yoga groups relative to placebo group (P < 0.001, P = 0.019, and P = 0.005, respectively). Regarding GPX level, it enhanced significantly only in CSP group following 8 weeks of intervention (P = 0.032). However, between group comparisons were not significant (P = 0.396). Catalase concentrations increased remarkably in CSP (P = 0.038) and CSP plus yoga group (P = 0.008), while between group comparison presented a significant increment in CSP plus yoga group relative to placebo following 8 weeks (P = 0.022). Furthermore, SOD/GPX ratio increased significantly in CSP (P = 0.018) and yoga (P = 0.033) groups, which between group comparisons showed significant changes only in CSP group relative to placebo and CSP plus yoga groups. (P = 0.002 and P = 0.028, respectively). Two months of yoga ( ) and yoga plus CSP intervention (P = 0.022, P=0.022 respectively) significantly increased the uric acid levels relative to baseline, while the changes were not significant through between group comparisons (P = 0.323).Table 6Comparing the oxidative stress status and inflammatory markers in study groups before and after intervention.The study groupVariablesPlacebo n = 19CSP n = 20Yoga n = 19CSP +yoga n = 20P-value ***TAC (mmol L−1) Before0.90 (0.08)0.91 (0.23)0.87 (0.10)0.93 (0.15)0.748** After0.91 (0.14)1.14 (0.28)1.18 (0.43)1.09 (0.16)0.182MD,95%CI0.01 (−0.04– 0.06)0.22 (0.05– 0.40)0.32 (0.04– 0.59)0.16 (0.10– 0.21)P-value *0.7810.0170.027<0.001Uric acid Before4.37 (0.64)4.58 (0.65)3.82 (0.67)3.12 (0.62)0.100** After4.34 (0.67)4.25 (0.69)4.57 (0.83)3.70 (0.95)0.323MD, 95% CI−0.04 (−0.27– 0.20)−0.33 (−0.66– 0.00)0.75 (0.13– 1.36)0.58 (0.10– 1.07)P-value *0.7460.0500.0220.022SOD (U mg−1 Hb) Before1469.84 (103.95)1470.50 (128.74)1531.97 (118.25)1516.56 (87.73)0.334** After1429.36 (189.84)1677.49 (101.96)a1625.12 (144.50)a1552.97 (98.83)a<0.001MD, 95% CI−40.49 (−119.00 –38.02)206.99 (131.37 –282.61)93.15 (29.82– 156.47)36.41 (5.37– 67.45)P-value *0.285<0.0010.0080.025GPX (U g−1 Hb) Before35.56 (5.48)33.97 (2.61)32.70 (2.28)35.53 (5.91)0.275** After35.45 (5.09)35.82 (3.26)33.32 (2.09)36.13 (6.13)0.396MD, 95% CI−0.11 (−1.24 to 1.02)1.85 (0.18–3.52)0.62 (−0.94– 2.18)0.60 (−0.27– 1.48)P-value*0.8380.0320.4060.160Catalase (U g−1 Hb) Before54.66 (10.58)50.73 (9.79)59.24 (9.40)60.74 (16.57)0.112** After54.62 (10.62)55.08 (12.54)61.93 (12.61)70.99 (14.09) a0.013MD, 95% CI−0.04 (−1.84– 1.75)4.36 (0.27–8.45)2.70 (−5.55– 10.95)10.25 (3.10– 17.40)P-value*0.9580.0380.4900.008SOD/GPX Before42.16 (6.21)43.59 (5.63)46.94 (3.54)43.62 (6.54)0.176** After40.91 (6.45)47.18 (5.03)a, d48.79 (3.38)43.84 (6.17)0.002MD, 95% CI−1.24 (−3.71 to 1.22)3.58 (0.70–6.46)1.85 (0.18–3.53)0.22 (−0.85– 1.29)P-value*0.2950.0180.0330.667MDA (nmol mL−1) Before3.63 (0.85)3.44 (1.37)3.96 (1.64)3.15 (0.95)0.369** After3.63 (0.61)2.94 (0.95)2.81 (1.13)a2.41 (1.16)a0.001MD, 95% CI0.00 (−0.41– 0.42)−0.50 (−0.93 to −0.07)−1.15 (−1.81 to −0.49)−0.74 (−1.21 to −0.27)P-value*0.9850.0250.0020.004TOS (μmol L−1) Before28.65 (1.04)29.47 (2.05)29.97 (2.58)27.50 (4.73)0.143** After28.24 (2.02)26.51 (3.62)26.45 (5.53)25.12 (3.73)0.261MD, 95% CI−0.41 (−1.37– 0.56)−2.95 (−4.55 to −1.36)−3.52 (−6.36 to −0.69)−2.38 (−4.58 to −0.17)P-value*0.3790.0010.0190.036 OSI Before31.90 (2.84)34.04 (8.30)33.44 (4.18)29.58 (5.78)0.164** After31.64 (4.97)26.08 (7.62)24.12 (8.61)24.76 (3.84)0.061MD, 95% CI−0.26 (−2.48 to 1.96)−7.95 (−11.25 to −4.66)−9.31 (−14.50 to −4.13)−4.82 (−8.20 to −1.45)P-value *0.806<0.0010.0020.008hs-CRP (ng ml−1) Before10.53 (4.34)10.45 (2.70)6.24 (2.20)8.11 (5.04)0.110** After11.54 (4.47)9.91 (1.32)7.02 (2.33)6.91 (5.03)0.063MD, 95% CI1.01 (−0.80– 2.83)−0.53 (−1.83– 0.77)0.78 (−1.56–3.13)−1.20 (−3.02–0.62)P-value *0.2490.3940.4790.180TNF-α (ng ml−1) Before15.50 (3.36)16.09 (4.14)15.26 (5.01)16.12 (2.79)0.913** After16.24 (3.72)14.24 (3.73)a12.84 (5.09)a13.47 (2.54)a<0.001MD, 95% CI0.74 (−0.73 to 2.22)−1.85 (−2.88 to −0.82)−2.41 (−3.29 to −1.54)−2.65 (−3.48 to −1.82) P-value*0.2970.002<0.001<0.001Means ± SD are presented for normally distributed data.P-value * was reported based on paired sample t test.P-value ** was reported based on ANOVA for Pre-intervention.P-value *** was reported based on analysis of covariance (ANCOVA) after adjustment of Pre-intervention and potential confounder as education, drugs, age, duration, energy and BMI.CSP Camelina seed powder, MD mean difference (mean after – mean before), TAC total antioxidant capacity, SOD superoxide dismutase, GPX glutathione peroxidase, MDA malondialdehyde, TOS total oxidant status, OS oxidative stress index, hs-CRP high sensitivity-C reactive protein, TNF-α tumor necrosis factor-α.aP-value less than 0.05 vs. placebo group.bP-value less than 0.05 vs. camelina group.cP-value less than 0.05 vs. yoga group.dP-value less than 0.05 vs. camelina plus yoga group. Table 6Comparing the oxidative stress status and inflammatory markers in study groups before and after intervention.The study groupVariablesPlacebo n = 19CSP n = 20Yoga n = 19CSP +yoga n = 20P-value ***TAC (mmol L−1) Before0.90 (0.08)0.91 (0.23)0.87 (0.10)0.93 (0.15)0.748** After0.91 (0.14)1.14 (0.28)1.18 (0.43)1.09 (0.16)0.182MD,95%CI0.01 (−0.04– 0.06)0.22 (0.05– 0.40)0.32 (0.04– 0.59)0.16 (0.10– 0.21)P-value *0.7810.0170.027<0.001Uric acid Before4.37 (0.64)4.58 (0.65)3.82 (0.67)3.12 (0.62)0.100** After4.34 (0.67)4.25 (0.69)4.57 (0.83)3.70 (0.95)0.323MD, 95% CI−0.04 (−0.27– 0.20)−0.33 (−0.66– 0.00)0.75 (0.13– 1.36)0.58 (0.10– 1.07)P-value *0.7460.0500.0220.022SOD (U mg−1 Hb) Before1469.84 (103.95)1470.50 (128.74)1531.97 (118.25)1516.56 (87.73)0.334** After1429.36 (189.84)1677.49 (101.96)a1625.12 (144.50)a1552.97 (98.83)a<0.001MD, 95% CI−40.49 (−119.00 –38.02)206.99 (131.37 –282.61)93.15 (29.82– 156.47)36.41 (5.37– 67.45)P-value *0.285<0.0010.0080.025GPX (U g−1 Hb) Before35.56 (5.48)33.97 (2.61)32.70 (2.28)35.53 (5.91)0.275** After35.45 (5.09)35.82 (3.26)33.32 (2.09)36.13 (6.13)0.396MD, 95% CI−0.11 (−1.24 to 1.02)1.85 (0.18–3.52)0.62 (−0.94– 2.18)0.60 (−0.27– 1.48)P-value*0.8380.0320.4060.160Catalase (U g−1 Hb) Before54.66 (10.58)50.73 (9.79)59.24 (9.40)60.74 (16.57)0.112** After54.62 (10.62)55.08 (12.54)61.93 (12.61)70.99 (14.09) a0.013MD, 95% CI−0.04 (−1.84– 1.75)4.36 (0.27–8.45)2.70 (−5.55– 10.95)10.25 (3.10– 17.40)P-value*0.9580.0380.4900.008SOD/GPX Before42.16 (6.21)43.59 (5.63)46.94 (3.54)43.62 (6.54)0.176** After40.91 (6.45)47.18 (5.03)a, d48.79 (3.38)43.84 (6.17)0.002MD, 95% CI−1.24 (−3.71 to 1.22)3.58 (0.70–6.46)1.85 (0.18–3.53)0.22 (−0.85– 1.29)P-value*0.2950.0180.0330.667MDA (nmol mL−1) Before3.63 (0.85)3.44 (1.37)3.96 (1.64)3.15 (0.95)0.369** After3.63 (0.61)2.94 (0.95)2.81 (1.13)a2.41 (1.16)a0.001MD, 95% CI0.00 (−0.41– 0.42)−0.50 (−0.93 to −0.07)−1.15 (−1.81 to −0.49)−0.74 (−1.21 to −0.27)P-value*0.9850.0250.0020.004TOS (μmol L−1) Before28.65 (1.04)29.47 (2.05)29.97 (2.58)27.50 (4.73)0.143** After28.24 (2.02)26.51 (3.62)26.45 (5.53)25.12 (3.73)0.261MD, 95% CI−0.41 (−1.37– 0.56)−2.95 (−4.55 to −1.36)−3.52 (−6.36 to −0.69)−2.38 (−4.58 to −0.17)P-value*0.3790.0010.0190.036 OSI Before31.90 (2.84)34.04 (8.30)33.44 (4.18)29.58 (5.78)0.164** After31.64 (4.97)26.08 (7.62)24.12 (8.61)24.76 (3.84)0.061MD, 95% CI−0.26 (−2.48 to 1.96)−7.95 (−11.25 to −4.66)−9.31 (−14.50 to −4.13)−4.82 (−8.20 to −1.45)P-value *0.806<0.0010.0020.008hs-CRP (ng ml−1) Before10.53 (4.34)10.45 (2.70)6.24 (2.20)8.11 (5.04)0.110** After11.54 (4.47)9.91 (1.32)7.02 (2.33)6.91 (5.03)0.063MD, 95% CI1.01 (−0.80– 2.83)−0.53 (−1.83– 0.77)0.78 (−1.56–3.13)−1.20 (−3.02–0.62)P-value *0.2490.3940.4790.180TNF-α (ng ml−1) Before15.50 (3.36)16.09 (4.14)15.26 (5.01)16.12 (2.79)0.913** After16.24 (3.72)14.24 (3.73)a12.84 (5.09)a13.47 (2.54)a<0.001MD, 95% CI0.74 (−0.73 to 2.22)−1.85 (−2.88 to −0.82)−2.41 (−3.29 to −1.54)−2.65 (−3.48 to −1.82) P-value*0.2970.002<0.001<0.001Means ± SD are presented for normally distributed data.P-value * was reported based on paired sample t test.P-value ** was reported based on ANOVA for Pre-intervention.P-value *** was reported based on analysis of covariance (ANCOVA) after adjustment of Pre-intervention and potential confounder as education, drugs, age, duration, energy and BMI.CSP Camelina seed powder, MD mean difference (mean after – mean before), TAC total antioxidant capacity, SOD superoxide dismutase, GPX glutathione peroxidase, MDA malondialdehyde, TOS total oxidant status, OS oxidative stress index, hs-CRP high sensitivity-C reactive protein, TNF-α tumor necrosis factor-α.aP-value less than 0.05 vs. placebo group.bP-value less than 0.05 vs. camelina group.cP-value less than 0.05 vs. yoga group.dP-value less than 0.05 vs. camelina plus yoga group. Comparing the oxidative stress status and inflammatory markers in study groups before and after intervention. Means ± SD are presented for normally distributed data. P-value * was reported based on paired sample t test. P-value ** was reported based on ANOVA for Pre-intervention. P-value *** was reported based on analysis of covariance (ANCOVA) after adjustment of Pre-intervention and potential confounder as education, drugs, age, duration, energy and BMI. CSP Camelina seed powder, MD mean difference (mean after – mean before), TAC total antioxidant capacity, SOD superoxide dismutase, GPX glutathione peroxidase, MDA malondialdehyde, TOS total oxidant status, OS oxidative stress index, hs-CRP high sensitivity-C reactive protein, TNF-α tumor necrosis factor-α. aP-value less than 0.05 vs. placebo group. bP-value less than 0.05 vs. camelina group. cP-value less than 0.05 vs. yoga group. dP-value less than 0.05 vs. camelina plus yoga group. About oxidative stress biomarkers, while TOS and OSI declined significantly following CSP, yoga, and combined CSP plus yoga treatments compared with baselines, they did not change significantly when compared them between the four studied groups through ANCOVA test (P = 0.261 and P = 0.061, respectively). MDA levels reduced significantly in CSP, yoga, and combined CSP plus yoga groups in within group comparisons. Between group evaluations showed that MDA concentration declined significantly in yoga and CSP plus yoga groups relative to placebo (P = 0.017 and P < 0.001, respectively). Regarding inflammatory indices, TNF-α levels decreased significantly after 8 weeks of interventions in CSP, yoga, and combined CSP plus yoga groups. Furthermore, between group comparisons reveled a significant decrement in CSP, yoga, and combined CSP plus yoga groups compared with the placebo group (P < 0.001, P = 0.033, and P < 0.001, respectively). hs-CRP concentrations did not change significantly in within-and between-group comparisons in all studied groups(P≥0.05). Discussion The findings from the current randomized, controlled parallel trial showed that CSP supplementation and yoga performance combination significantly promoted glucose homeostasis parameters, including McAuley-index, Quick-index, and also CSP and yoga alone or their combination had promising effects on TNF-α. Combined CSP plus yoga had a greater effect on improving these glycemic and inflammatory indices. Moreover, the results suggest that CSP supplementation plus yoga had favorable effects on MDA levels in T2DM patients and these effects could be increased with performing yoga too. The study of Musazadeh et al. [35] was the first randomized clinical trial to assess the combined effects of caloric restriction and camelina sativa oil (CSO) on penitents with non-alcoholic fatty liver disease (NAFLD). Their findings showed that insulin concentration, HOMA-IR, QUICKI, LPS, TAC, SOD, GPX, and MDA improved significantly only in the CSO group and hs-CRP decreased significantly in the CSO and placebo groups. Yari et al. [36] demonstrated that 30 g whole flaxseed powder, because of the high content of omega-3, fiber, and its other components, significantly reduced FBS, insulin, and indices of insulin resistance, improved insulin sensitivity, compared to the beginning of the study, while hs-CRP and TNF-α showed no significant differences in the group receiving 30 g whole flaxseed powder at the 12th week. In contrast, Kavyani et al [37] in an umbrella meta-analysis found that supplementation of omega-3 polyunsaturated fatty acids in adults can improve CRP, TNF-α, and interleukin 6 (IL-6) concentrations under various health conditions. Furthermore, a meta-analysis conducted by Tamtaji et al. [38] indicated that flaxseed oil supplementation, as a rich source of omega-3, decreased IL-6 and MDA levels, and increased TAC among patients with metabolic syndrome (MetS) and related disorders. In a study by Kaviani et al. [39] which aimed to investigate the effects of co-supplementing CSO and a prebiotic as modulators of the gut microbiota on cardiometabolic risk factors and mental health in NAFLD patients, co-supplementing CSO and resistant dextrin significantly decreased the levels of insulin concentration, HOMA-IR, hs-CRP, endotoxin, cortisol, and MDA and increased the levels of TAC and SOD in the intervention group compared with the placebo group. However, no significant changes were found in the levels of FPS, QUICKI, catalase, GPX or uric acid levels. However, Schwab et al. [40] reported that a diet enriched in CSO did not affect fasting, post-load plasma glucose or serum insulin concentrations in subjects with impaired glucose metabolism (IGM). These conflicting findings may be attributed to the designed diet, omega-6 to omega-3 ratio in the diet, the placebo group, the baseline glycemic index levels, the intervention duration, the kind and doses of supplements, as well as the medical condition of the patients. The suggested anti-hyperglycemic mechanisms of action by CSP that may affect insulin resistance are mainly related to its omega-3 fatty acid content. By altering mitochondrial bioenergetics and endoplasmic reticulum stress and by upregulating peroxisome proliferator-activated receptor gamma (PPAR-γ), one of the primary regulators of glucose homeostasis, omega-3 fatty acids are believed to ameliorate insulin resistance [41]. Targeting the gut microbiota, omega-3 improves glycemic indices. By balancing the gut microbiota, glucose homeostasis may be affected by increased secretion of gut hormones, such as glucagon-like peptide-1 (GLP-1), GLP-2, gastric inhibitory polypeptides, and peptide YY (PYY); lowering body weight, and increasing concentrations of short-chain fatty acids (SCFA), particularly butyrate [42]. Additionally, binding of SCFA to specific G-protein-coupled receptors (GPCRs) (i.e., GPR41 and GPR43) causes the release of GLP-1, GLP-2, and PYY [43]. Butyrate, as an SCFA, also increases GLP-2, the activation of the peroxisome proliferator-activated receptor gamma (PPAR-γ), upregulating the mucin-associated gene expression, and improving tight junction protein transcription, which in turn reduces inflammation and insulin resistance [44]. Furthermore, SCFA such as butyrate decreases the production of ROS by suppressing IκB kinase (IKK), which separates nuclear factor kappa B (NF-κB) from inhibitor of nuclear factor kappa B (IKBα) [45], increasing the production of antioxidant enzymes in plasma, modulating the transcription of forkhead box O3 (FOXO3A) and metallothionein 2 (MT2) by inhibiting histone deacetylases [46], lowering the activity of colonic myeloperoxidase [47] and activating p38/MAPK, c-Jun N-terminal kinase, and mitogen-activated protein kinase (MAPK/ERK) [48]. When dysbiosis is present, gram-negative bacteria produce more lipopolysaccharides (LPS) [49], which aggravates insulin resistance by increasing the expression of pro-inflammatory cytokines such as TNF-α, IL-1, and IL-6 [50] by binding to toll-like receptor 4 (TLR4)[49], decreasing insulin action by preventing phosphorylation of the insulin receptor substrate (IRS)-1 and IRS-2, and lowering or even suppressing the expression of IRS-1 and IRS-2 [51]. CSP, as a rich plant source of omega-3, improves intestinal permeability and increases the endogenous activity of intestinal alkaline phosphatase (ALP), which is involved in the production of LPS. It also inhibits the TLR4-induced signaling pathway by modulating the G protein-coupled receptor (GPR)-120 [52]. In conclusion, omega-3 may improve gut microbial dysbiosis, which may protect against inflammation, oxidative stress damage, and insulin resistance [35]. Furthermore, omega-3 reduces inflammation by controlling PPAR-γ [53]. By attaching to this receptor, omega-3 detaches the PPAR-γ repressor, and a coactivator is attached to the PPAR-γ [54]. PPAR- γ is a strong inhibitor of NF-ĸB, which is the primary regulator of cytokine production in the immune system [55]. Researches indicated that CSO increased the expression of the PPAR-γ protein [56, 57]. Additionally, omega-3 have been identified as the natural agonists of PPAR-γ [58]. Moreover, omega-3 leads to replacement of arachidonic acid in lipid rafts with changes in fatty acids [37]. This substitution inhibits TLR-4, −2, and −6 signaling, and suppresses pro-inflammatory molecules like NADPH-oxidase (NOX) [59]. Moreover, the anti-inflammatory effects of omega-3 may be related to the suppression of endocannabinoids, ethanolamides, and oxylipins, as well as endocannabinoid system modulation [60]. The pathogenesis of insulin resistance and T2DM is known to be significantly influenced by oxidative stress [61]. Anti-oxidant properties of omega-3 fatty acids are primarily linked to modifications in cellular membrane architecture that reduce the formation of ROS and lipid peroxidation [62, 63]. Moreover, camelina sativa’s antioxidant properties are aided by other substances such phytosterols, carotenoids, and tocopherols [64]. Furthermore, ALA in CSP is a precursor of long-chain docosahexaenoic acid. It has been demonstrated that docosahexaenoic acid increases the activity of glutathione reductase, GPX, and SOD and decreases MDA levels [65]. In subjects with T2DM, in addition to nutritional strategies, physical activity is effective in preventing and managing the disease’s complications [15], and the results of our study confirm this issue. Yoga may enhance glucose tolerance and insulin sensitivity in T2DM individuals [66]. Also, Regular yoga practice remarkably attenuated oxidative stress, inflammation, and improved antioxidant levels [67]. The increase in antioxidant defense enzymes, including SOD, GPX, glutathione S-transferase (GST), and catalase activity, improves antioxidant defense mechanisms. It has been demonstrated that practicing yoga greatly increases the sensitive indicator of the antioxidant systems [68]. Lim et al. [67] reported that yoga led to a significant reduction in MDA and an increase in serum total glutathione, GST, GPX, catalase and SOD activity in healthy adults. In a study aimed at assessing the effect of yoga on anthropometry, blood pressure, glycemic control, and oxidative stress in T2DM, Hegde et al. [67] showed a significant reduction in FBS, PPBG, HbA1c, and MDA and an increase in glutathione. There were no differences in SOD in the yoga group at follow-up. In another trial on prediabetes patients done by Hegde et al. [69], yoga intervention resulted in a significant decline in MDA, compared to the control group. In comparison with the control, there was a significant improvement in fasting glucose levels at follow-up. No significant improvement in HbA1c or any of the antioxidants was observed. Yadav et al. [70] in a randomized controlled trial on adults with MetS, observed a significant decrease in IL-6, whereas there was a significant increase in SOD level. In another study done by Viswanathan et al. [71], there was a significant reduction in blood glucose level, HbA1c, IL-6, and TNFα in the yoga group as compared to the non-yoga group. The contradictory findings may be attributed to the sample size. The mechanisms underlying the apparent beneficial effects of yoga therapy on diabetes risk profiles are yet unclear. Sympathetic activation and hypothalamic–pituitary–adrenal (HPA) axis dysregulation have also been linked to the development and exacerbation of several risk factors for T2DM, such as insulin resistance, impaired glucose tolerance, oxidative stress, and proinflammatory states [72]. First, yoga may mitigate the negative impact of stress and promote multiple positive downstream effects on metabolic function, neuroendocrine status, and associated inflammatory responses, by improving well-being and reducing reactivity and activation of the hypothalamic-pituitary-adrenal (HPA) axis and the sympathoadrenal system [72]. Second, yogic practices may shift the autonomic nervous system balance from predominantly sympathetic to parasympathetic by directly increasing parasympathetic output, potentially through vagal stimulation, leading to positive changes in inflammatory profiles and oxidative stress [73]. Third, yoga may also promote beneficial changes in autonomic balance and associated metabolic and inflammatory responses by selectively activating particular brain structures and neurochemical systems linked to attention and positive affect. Additionally, yoga may increase resilience to stress, a factor that has been linked to improved outcomes in T2DM [72]. The beneficial effects of yoga on modulating the transcription of genes responsible for downstream pro-inflammatory and anti-inflammatory effects have been reported [74]. Additionally, yoga has a positive impact on the body’s endocrine and exocrine glands, improving insulin sensitivity and decreasing insulin resistance, which lowers FBS and PPBG levels and improves glycemic control. It also increases the pancreatic B-cells’ sensitivity to glucose signals [75]. To the best of our knowledge, this was the pioneer clinical trial that evaluated the effects of a combination of CSP and yoga among women with T2DM. High compliance rate of the participants to the treatment in all groups was a strength points of this investigation. However, it had some limitations. The limitation of this trial was the design of the study which was semi blinded. Due to the nature of the exercise intervention participants are only blinded to CSP intervention. Furthermore, the sample size was determined on the basis of changes in hs-CRP by considering 80% power and 95% confidence. In the case of this particular variable, the power obtained was sufficient to produce significant results. However, for some other variables, it seems that a larger sample size and a higher power are needed to attain statistical significance. Short intervention time and selecting only females as participants of the study were other important limitations of this trial. Thus, long-term interventions with both female and male participants might result in greater effects. So, the generalization of our results is limited and replication in large sample size and long duration studies is required. Conclusion We found a favorable effect of co-treatment of CSP and yoga for 8 weeks in women with T2DM on glycemic indices and oxidative stress. Furthermore, the results suggest that CSP supplementation had favorable effects on oxidative stress and inflammatory parameters in T2DM patients and these effects could be increased with performing yoga too.